Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells

Molecular and Cellular Biochemistry

Volumn 392, Issue 1-2, 2014, Pages 161-174

  Gornowicz, Agnieszka ^a   Kałuża, Zbigniew ^b   Bielawska, Anna ^a   Gabryel Porowska, Halina ^a   Czarnomysy, Robert ^a   Bielawski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

Author keywords

Breast cancer; Cisplatin; Combined therapy; Dinuclear platinum(II) complexes; Monoclonal antibody anti MUC1

Indexed keywords

CISPLATIN; COLLAGEN; CYTOTOXIC AGENT; LIPOCORTIN 5; MONOCLONAL ANTIBODY; MUCIN 1 ANTIBODY; PT 12; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MUC1 PROTEIN, HUMAN; MUCIN 1; PLATINUM COMPLEX;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING ASSAY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MCF 7 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; BREAST TUMOR; DRUG EFFECTS; FEMALE; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MUCIN-1; ORGANOPLATINUM COMPOUNDS;

EID: 84905178125     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2018-2     Document Type: Article

References (28)

1. Li Y, Yi H, Yao Y, Liao X, Xie Y, Yang J, Yan Z, Wang L, Lu S, Kuang Y, Gu M, Fei J, Wang Z, Huang L (2011) The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin. PLoS ONE 6:e19102
2. Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, Kawano T, Kharbanda S, Kufe D (2011) MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal 4:ra9
3. Singh R, Bandyopadhyay D (2007) MUC1 a target molecule for cancer therapy. Cancer Biol Ther 6:481-486 (Pubitemid 47328319)
4. Raina D, Kosugi M, Ahamd R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D (2011) Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 10:806-816
5. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D (2007) The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 27:992-1004 (Pubitemid 47488189)
6. Senapati S, Das S, Batra SK (2010) Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci 35:236-245
7. Hisatsune A, Nakayama H, Kawasaki M, Horie I, Miyata T, Isohama Y, Kim KC, Katsuki H (2011) Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem Biophys Res Commun 405:377-381
8. Zanetti JS, Soave DF, Oliveira-Costa JP, Silveira GG, Ramalho LNZ, Garcia SB, Zucoloto S, Ribeiro-Silva A (2011) The role of tumor hypoxia in MUC1-positive breast carcinomas. Virchows Arch 459:367-375
9. Brabec V, Kasparkova J (2005) Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131-146 (Pubitemid 41267064)
10. Farrell N (2004) Polynuclear platinum drugs. In: Sigel A, Sigel H (eds) Metal ions in biological systems. Basel, Marcel Dekker, Inc, New York, pp 251-296
11. Muchova T, Quintal SM, Nicholas P, Farrell NP, Brabec V, Kasparkova J (2012) Antitumor bifunctional dinuclear PtII complex BBR3535 forms interduplex DNA crosslinks under molecular crowding conditions. J Biol Inorg Chem 17:239-245
12. Wheate NJ, Collins JG (2005) Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr Med Chem Anticancer Agents 5:267-279 (Pubitemid 40645594)
13. Mangrum JB, Farrell NP (2010) Excursions in polynuclear platinum DNA binding. Chem Commun 46:6640-6650
14. Carmichael J, Degraff W, Gazdar A, Minna J, Mitchell J (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47:96
15. Peterkofsky B, Pałka J, Wilson S, Takeda K, Shah V (1991) Elevated activity of low molecular weight insulin- like growth factor binding proteins in sera of vitamin-c deficient and fasted guinea pigs. Endocrinology 128:1769-1779
16. Westermann B (2008) Molecular machinery of mitochondrial fusion and fission. J Biol Chem 283:13501-13505
17. Singh SK, Moretta D, Almaguel F, Wall NR, De Leon M, De Leon D (2007) Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating surviving cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 25:363-372 (Pubitemid 351455002)
18. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626-629 (Pubitemid 39006738)
19. Wang L, Chen H, Liu F, Madigan MC, Power CA, Hao J, Patterson KI, Pourgholami MH, O'Brien PM, Perkins AC, Li Y (2011) Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 300:122-133
20. Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, Perkins AC, Kearsley JH, Li Y (2011) Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS ONE 6:e24405
21. Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH, Keydar I (2006) MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expression. Mol Cancer 5:57
22. Mammoto A, Inger DE (2009) Cytoskeletal control of growth and cell fate switching. Curr Opin Cell Biol 21:864-870
23. Gonzalez MG, Bhattacharya R, Hard WG, Jones JCR (2010) Transdominant regulation of integrin function: mechanism of crosstalk. Cell Signal 22:578-583
24. Kociecka B, Surazynski A, Miltyk W, Palka J (2010) The effect of telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells. Eur J Pharmacol 628:51-56
25. Bitler BG, Menzl I, Huerta CL (2009) Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 15:100-109
26. Bielawski K, Czarnomysy R, Muszyńska A, Bielawska A, Popławska B (2013) Cytotoxicity and induction of apoptosis of human breast cancer cells by novel platinum(II) complexes. Environ Toxicol Pharmacol 35:254-264
27. Brunelle JK, Zhang B (2010) Apoptosis assays for quantifying the bioactivity of anticancer drug products. Drug Resist Updat 13:172-179
28. Ly JD, Grubb DR, Lawen A (2003) The mitochondrial membrane potential (deltapsi(m)) in apoptosis. Apoptosis 8:116-128